AMIX Stock Catalyst: Autonomix Medical Reports Positive Subgroup Results from First-in-Human Study

Autonomix Medical, Inc. announced on 2025-11-17 Autonomix Medical, Inc. reported positive subgroup results from a post-hoc exploratory subgroup analysis of its first-in-human proof-of-concept study evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with severe pancreatic cancer pain.

The announcement cited 14.53 points, 26.07 points, 8.15 points, 25.56 points, 8.33 points, 18.06 points, 32.48 points, 11.85 points, 25.00 points, 19.44 points, 53.3%, 59.2%, 65.6%, 5 million, and 5.0 million.

Autonomix Medical, Inc. Common Stock has a free float of 6,533,600 shares and 6,907,700 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.